Don't miss out on the latest news, evidence and CPD opportunities on medicines and medical tests - sign up today.
Relevant, timely and evidence-based information for Australian health professionals and consumers.
NPS MedicineWise produces relevant, timely and evidence-based information for Australian health professionals and consumers. Our publications include Australian Prescriber and RADAR plus articles and e-newletters. All our publications are available online and via subscription, free of charge.
Read about our high-profile projects, events and campaigns or join our conversations on Facebook and Twitter.
| Title | Date |
|---|---|
| Dose confusion with paracetamol/ibuprofen combinations | 06 June 2017 |
| Quick primer on idarucizumab and NOAC-associated bleeding | 20 April 2017 |
| Idarucizumab (Praxbind) for dabigatran (Pradaxa) reversal: what you should know | 19 April 2017 |
| Why tackle COPD now? | 01 March 2017 |
| GP survey results: where to start with osteoporosis | 16 February 2017 |
| The value of spirometry in clinical practice | 02 February 2017 |
If you are a journalist seeking comment on a story or more information on any of our programs or campaigns please contact the NPS MedicineWise media team on 02 8217 8667
For urgent media requests outside of office hours, please call 0419 618 365. If your request is not urgent you can also email an enquiry.
Our latest research and evaluations is published regularly in:
Australian Prescriber is an independent peer-reviewed journal that provides critical commentary on drugs and therapeutics for health professionals.
Peak stories have included the top 10 most expensive drugs, eradication of Hepatitis C, drug seeking behaviours in people and more.
RADAR provides health professionals with timely information on new drugs, medical tests and changes to listings on the Pharmaceutical Benefits Scheme and Medicare Benefits Schedule.
Peak stories have included warfarin, campaigns urging doctors to seeing health reps, and treating Hepatitis C.
If you’re a journalist and would like help transforming our research and evidence into something accessible for the public, please contact our media team.